CBER’s Peter Marks offers insights on a new Rare Disease Hub, upcoming accelerated approval guidance

BY ALEXANDER GAFFNEY, MS, RAC

This week, PETER MARKS, director of FDA’s Center for Biologics Evaluation and Research (CBER), spoke at several sessions of the Drug Information Association (DIA) annual meeting. AgencyIQ has the highlights, with new information on a “Rare Disease Hub” modeled as a sort of Center of Excellence for rare diseases.

Fill out the form to read the full article.